Extracorporeal photopheresis is a valuable treatment option in steroid-refractory or steroid-dependent acute graft versus host disease—experience with three different approaches

Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival

(2018) Marietta Nygaard et al.   BONE MARROW TRANSPLANTATION

Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease

(2016) I García-Cadenas et al.   BONE MARROW TRANSPLANTATION

Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies

(2014) Iman Abu-Dalle et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies

(2014) Øystein Bruserud et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure

(2014) E. Das-Gupta et al.   HAEMATOLOGICA

Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials

(2013) S Sengsayadeth et al.   BONE MARROW TRANSPLANTATION

Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease

(2013) Y. Inamoto et al.   HAEMATOLOGICA

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

(2012) Paul J. Martin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement

(2009) Paul J. Martin et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION